Anixa Biosciences Completes Treatment Of First Patient Cohort In Ovarian Cancer CAR-T Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences (NASDAQ:ANIX) has completed the treatment of the first patient cohort in its ongoing clinical trial of CAR-T therapy for ovarian cancer, in partnership with Moffitt Cancer Center. The first cohort received the same dose of engineered T-cells, with no dose-limiting toxicities observed. The trial will now begin enrolling patients in the second dose cohort, who will receive three times the cell dose compared to the first cohort. The study aims to evaluate the therapy's safety, determine the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor (FSHR), and preliminarily assess clinical activity.
October 13, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences has successfully completed the first phase of its clinical trial for CAR-T therapy for ovarian cancer. The positive safety data and the progression to the next phase of the trial could potentially have a positive impact on the company's stock.
The successful completion of the first phase of the clinical trial and the positive safety data are significant milestones for Anixa Biosciences. This could potentially attract more investors, leading to an increase in the company's stock price. However, the final impact will depend on the results of the next phases of the trial.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100